The Pirna CHAPIR Regulates Cardiac Hypertrophy by Controlling METTL3-dependent N 6 -Methyladenosine Methylation of Parp10 Mrna
Xiang-Qian Gao,Yu-Hui Zhang,Fang Liu,Murugavel Ponnusamy,Xue-Mei Zhao,Lu-Yu Zhou,Mei Zhai,Cui-Yun Liu,Xin-Min Li,Man Wang,Chan Shan,Pei-Pei Shan,Yin Wang,Yan-Han Dong,Li-Li Qian,Tao Yu,Jie Ju,Tao Wang,Kai Wang,Xin-Zhe Chen,Yun-Hong Wang,Jian Zhang,Pei-Feng Li,Kun Wang
DOI: https://doi.org/10.1038/s41556-020-0576-y
IF: 21.3
2020-01-01
Nature Cell Biology
Abstract:PIWI-interacting RNAs (piRNAs) are abundantly expressed during cardiac hypertrophy. However, their functions and molecular mechanisms remain unknown. Here, we identified a cardiac-hypertrophy-associated piRNA (CHAPIR) that promotes pathological hypertrophy and cardiac remodelling by targeting METTL3-mediated N 6 -methyladenosine (m 6 A) methylation of Parp10 mRNA transcripts. CHAPIR deletion markedly attenuates cardiac hypertrophy and restores heart function, while administration of a CHAPIR mimic enhances the pathological hypertrophic response in pressure-overloaded mice. Mechanistically, CHAPIR–PIWIL4 complexes directly interact with METTL3 and block the m 6 A methylation of Parp10 mRNA transcripts, which upregulates PARP10 expression. The CHAPIR-dependent increase in PARP10 promotes the mono-ADP-ribosylation of GSK3β and inhibits its kinase activity, which results in the accumulation of nuclear NFATC4 and the progression of pathological hypertrophy. Hence, our findings reveal that a piRNA-mediated RNA epigenetic mechanism is involved in the regulation of cardiac hypertrophy and that the CHAPIR–METTL3–PARP10–NFATC4 signalling axis could be therapeutically targeted for treating pathological hypertrophy and maladaptive cardiac remodelling.